Botox would-be rival blocked by judge; FDA rejects expanded use for Dacogen;

@FiercePharma: AARP issues its latest drug-price report ('relentless' inflation, etc); PhRMA issues its latest assault on that report. Article | Follow @FiercePharma

> Allergan ($AGN) won an injunction blocking Merz Pharma's attempts to launch a Botox rival; a judge ruled Merz misappropriated trade secrets. News

> South Africa's Aspen Pharmacare--19% owned by GlaxoSmithKline ($GSK)--posted a big increase in sales outside its home market, with Asia Pacific revenues three times last year's figures. Report

> Discovery Labs ($DSCO) wins an FDA nod for its respiratory drug Surfaxin, used to treat premature babies, after years of trying. More

> Almost three-quarters of Incivek patients had undetectable hepatitis C levels 12 weeks after treatment with combo therapy ended, study data showed, compared with 45% of patients whose therapy did not include the Vertex Pharmaceuticals drug. Report

> Sanofi ($SNY) among the healthcare companies asked to take haircuts on Greek bonds it accepted as payment for past-due drug bills. Story

> Eisai gets an expected thumbs-down from the FDA for expanded use of its Dacogen leukemia drug, after advisory committee voted against. Report

> U.S. veterans of the Iraq war were more likely to receive prescriptions for high-powered painkillers if they had been diagnosed with mental health problems. Article

> Sandoz had its hand slapped by the U.K.'s Prescription Medicines Code of Practice Authority for distributing water bottles and backpacks to patients treated with a growth hormone drug. Report

Biotech News

@FierceBiotech: Protein-based nanofiber envisioned for use in delivering cardio, Alzheimer's drugs. Story | Follow @FierceBiotech

@JohnCFierce: Mersana does an ADC development deal with Endo--$270M in biobucks. Release | Follow @JohnCFierce

@RyanMFierce: Not surprised. Accelrys (software for drug discovery labs) barely topped analyst EPS estimates for 4Q '11. More | Follow @RyanMFierce

> Positive Phase III sets stage for levomilnacipran NDA. News

> Mersana snaps up $270M cancer drug deal with Endo Pharma. Article

> CNS drug developers face long stretch in the clinic, poor odds of success. Story

> OpGen bags up to $17M in VC deal. Report

Biomarkers News

> Biomarkers warn of kidney injury after heart surgery. Story

> Biomarkers expose child cancer treatment heart risk. Article

> Mitochondria changes could track Alzheimer's disease. More

> Urine test could point out colon cancers. Item

Drug Delivery News

> Conceal drug delivery tech to avoid immune system wrath. Story

> With J&J deal undone, Orexo revamps drug delivery tech development. More

> Tekmira seeks court's rejection of Alnylam drug delivery patent suit. Article

> Protein-based nanofiber envisioned for drug delivery use. Item

Medical Device News

> Abbott, Merck keep companion Dx trend going with cancer test. Article

> Accelmed, Peregrine Ventures pump up NLT Spine's funding to $14.5M. News

> FDA warns Synthes facility over complaint handling procedures. More

> Roche tries to pressure Illumina to start talking. Item

And Finally... The FDA would like you to know certain skin-lightening creams, soaps and lotions may contain mercury. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.